Literature DB >> 7692714

Analysis of ELISA hepatitis C virus-positive blood donors population by polymerase chain reaction and recombinant immunoblot assay (RIBA). Comparison of second and third generation RIBA.

C Chicheportiche1, J F Cantaloube, P Biagini, P Aumont, F Donnadieu, J Escher, F Larabi, J P Zepitelli.   

Abstract

A new RIBA-3 (Chiron-Ortho Diagnostic System) was performed for discriminating uninterpretable results of RIBA-2. Recognition of antibodies to hepatitis C virus by RIBA-2 and RIBA-3 was compared among 95 ELISA-2 (second generation ELISA) positive blood donors and correlated with alanine-aminotransferase (ALAT) levels and viremia, using polymerase chain reaction (PCR). These studies led to three important conclusions. First, all ELISA-2-positive, RIBA-2-positive and ALAT-positive samples were found viremic compared with 73% of ELISA-2-positive, RIBA-2-positive and ALAT-negative samples. Then, the comparison of the different RIBAs allowed to conclude that RIBA-3 was more sensitive but less specific than RIBA-2. RIBA-3 was interesting to discriminate undetermined RIBA-2, owing to an improved specificity of C100-3 antigen. In fact, most of the C100-3 positive, RIBA-2 undetermined samples became RIBA-3 negative whereas C22-3 positive, RIBA-2 undetermined samples became RIBA-3 positive or undetermined. Finally, a significant correlation was found between the presence of antibodies against C33-c antigen and viremia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7692714

Source DB:  PubMed          Journal:  Acta Virol        ISSN: 0001-723X            Impact factor:   1.162


  3 in total

Review 1.  Hepatitis C in childhood.

Authors:  F Bortolotti
Journal:  Indian J Pediatr       Date:  1995 Sep-Oct       Impact factor: 1.967

2.  Definition of false-positive reactions in screening for hepatitis C virus antibodies.

Authors:  M Schröter; H H Feucht; P Schäfer; B Zöllner; S Polywka; R Laufs
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

3.  Study on reliability of commercially available hepatitis C virus antibody tests.

Authors:  H H Feucht; B Zöllner; S Polywka; R Laufs
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.